Literature DB >> 15496158

In vitro evidence for immune activating effect of specific AGE structures retained in uremia.

Griet Glorieux1, Ruediger Helling, Thomas Henle, Philippe Brunet, Reinhold Deppisch, Norbert Lameire, Raymond Vanholder.   

Abstract

BACKGROUND: Advanced glycation end-products (AGEs) have been identified to be accumulated in blood and tissues of patients with end-stage renal disease (ESRD). AGEs have been shown to modulate immune competent cell activities and in this way they may contribute to the progression of atherosclerosis. All studies in this context have been performed, however, with generated mix of glycation compounds, and not with structures similar to those encountered in uremia. In the present study, the immunologic effect of specific AGE compounds, known to be retained in uremia, has been evaluated.
METHODS: Four albumin preparations, modified chemically at lysine or arginine residues, respectively, to contain N-epsilon-carboxymethyllysine (CML albumin), N-epsilon-carboxyethyllysine (CEL albumin), glyoxal-induced imidazolinones (Arg I albumin) or methylglyoxal-induced imidazolinones (Arg II albumin) were applied. Their effect on chemiluminescence production, CD14 expression, and the DNA synthesis of calcitriol-differentiated HL-60 (monocyte/macrophage phenotype) was studied.
RESULTS: The phorbol 12-myristate 13-acetate (PMA)-stimulated chemiluminescence production of the calcitriol differentiated HL-60 cells was enhanced in the presence of CEL albumin (44.1 +/- 18.5 vs. 64.7 +/- 28.1 counts 10(3)/30 min) (P < 0.05), Arg I albumin (46.4 +/- 18.8 vs. 66.1 +/- 32.6 counts 10(3)/30 min) (P < 0.05) and CML albumin (41.9 +/- 25.5 vs. 60.9 +/- 5.5 counts 10(3)/30 min) (P= 0.0625) pointing to an increase in free radical production. The latter AGE compounds also significantly increased the calcitriol-induced CD14 expression on HL-60 cells (1675 +/- 796 vs. 2075 +/- 1044; 768 +/- 143 vs. 890 +/- 150; 647 +/- 63 vs. 716 +/- 69 mean fluorescence intensity) (P < 0.05, respectively) pointing to an increase in expression of the lipopolysaccharide (LPS) receptor. Finally, the DNA synthesis of the calcitriol-differentiated HL-60 cells was enhanced in the presence of Arg I albumin [34.5 +/- 4.6 vs. 27.7 +/- 9.7% 5-bromo-2'-deoxyuridine (BrdU)-positive cells] (P < 0.05) resulting in an increased cell proliferation.
CONCLUSION: Genuine AGE compounds, as they are encountered in the uremic condition, activate leukocyte response, and hence could play a role in uremia related atherogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15496158     DOI: 10.1111/j.1523-1755.2004.00961.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  17 in total

1.  Exploring post-translational arginine modification using chemically synthesized methylglyoxal hydroimidazolones.

Authors:  Tina Wang; Rendy Kartika; David A Spiegel
Journal:  J Am Chem Soc       Date:  2012-05-16       Impact factor: 15.419

2.  Ovalbumin modified with pyrraline, a Maillard reaction product, shows enhanced T-cell immunogenicity.

Authors:  Monika Heilmann; Anne Wellner; Gabriele Gadermaier; Anne Ilchmann; Peter Briza; Maren Krause; Ryoji Nagai; Sven Burgdorf; Stephan Scheurer; Stefan Vieths; Thomas Henle; Masako Toda
Journal:  J Biol Chem       Date:  2014-02-06       Impact factor: 5.157

3.  Circulating Advanced Glycation Endproducts and Long-Term Risk of Cardiovascular Mortality in Kidney Transplant Recipients.

Authors:  Camilo G Sotomayor; António W Gomes-Neto; Marco van Londen; Rijk O B Gans; Ilja M Nolte; Stefan P Berger; Gerjan J Navis; Ramón Rodrigo; Henri G D Leuvenink; Casper G Schalkwijk; Stephan J L Bakker
Journal:  Clin J Am Soc Nephrol       Date:  2019-09-17       Impact factor: 8.237

4.  Oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure.

Authors:  Seiji Ueda; Sho-ichi Yamagishi; Masayoshi Takeuchi; Keisuke Kohno; Ryo Shibata; Yuriko Matsumoto; Utako Kaneyuki; Toshiko Fujimura; Ayako Hayashida; Seiya Okuda
Journal:  Mol Med       Date:  2006 Jul-Aug       Impact factor: 6.354

5.  Benfotiamine reduces genomic damage in peripheral lymphocytes of hemodialysis patients.

Authors:  Nicole Schupp; Eva Maria Dette; Ursula Schmid; Udo Bahner; Michaela Winkler; August Heidland; Helga Stopper
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-05-29       Impact factor: 3.000

Review 6.  Management of protein-energy wasting in non-dialysis-dependent chronic kidney disease: reconciling low protein intake with nutritional therapy.

Authors:  Csaba P Kovesdy; Joel D Kopple; Kamyar Kalantar-Zadeh
Journal:  Am J Clin Nutr       Date:  2013-05-01       Impact factor: 7.045

7.  The effects of low-dose nepsilon-(carboxymethyl)lysine (CML) and nepsilon-(carboxyethyl)lysine (CEL), two main glycation free adducts considered as potential uremic toxins, on endothelial progenitor cell function.

Authors:  Jinzhou Zhu; Ke Yang; Yajun Jing; Run Du; Zhenbin Zhu; Lin Lu; Ruiyan Zhang
Journal:  Cardiovasc Diabetol       Date:  2012-08-01       Impact factor: 9.951

Review 8.  Immune dysfunction in uremia&#8212;an update.

Authors:  Gerald Cohen; Walter H Hörl
Journal:  Toxins (Basel)       Date:  2012-10-24       Impact factor: 4.546

Review 9.  What is new in uremic toxicity?

Authors:  Raymond Vanholder; Steven Van Laecke; Griet Glorieux
Journal:  Pediatr Nephrol       Date:  2008-03-07       Impact factor: 3.714

10.  Uraemic toxins and new methods to control their accumulation: game changers for the concept of dialysis adequacy.

Authors:  Griet Glorieux; James Tattersall
Journal:  Clin Kidney J       Date:  2015-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.